Previous 10 | Next 10 |
- Integrated analysis confirms addition of voclosporin to standard-of-care resulted in faster Renal Response compared to standard-of-care alone in lupus nephritis - - DDI study demonstrates no clinically meaningful interaction between voclosporin and MMF, supporting differenti...
Gainers: Inspire Medical Systems (INSP) +24%, GW Pharmaceuticals (GWPH) +15%, Aptevo Therapeutics (APVO) +14%, Galera Therapeutics (GRTX) +11%, DBV Technologies (DBVT) +10%.Losers: Esperion Therapeutics (ESPR) -15%, Aurinia Pharmaceuticals (AUPH)...
Apartment Investment and Management (AIV) -23%.SolarEdge Technologies (SEDG) -18% on Q3 earnings release.Pacific Biosciences of California (PACB) -10% on Q3 earnings release.Aurinia Pharmaceuticals (AUPH) -9% on suspending voclosporin program as Phase 2/3 study f...
Aurinia Pharmaceuticals (AUPH) down 10% after-hours after announcing topline data from the Phase 2/3 AUDREY clinical study evaluating voclosporin ophthalmic solution ((VOS)) for the potential treatment of dry eye syndrome ((DES)).The trial did not achieve statistical significance on...
Gainers: [[ANET]] +23.9%. [[JAKK]] +22.3%. [[MED]] +11.5%. [[INSP]] +10.1%. [[CDLX]] +9.5%.Losers: [[SEDG]] -19.1%. [[AUPH]] -10.3%. [[PACB]] -6.8%. [[IPI]] -5.8%. [[BRKR]] -4.6%. For further details see: ANET, JAKK, PACB and SEDG among after-hours movers
- The trial did not achieve statistical significance on the primary endpoint of ≥ 10mm improvement in Schirmer Tear Test (STT) at 4 weeks – - Company to suspend development program for voclosporin ophthalmic solution (VOS) - - Aurinia to host conference c...
Aurinia Pharmaceuticals (AUPH) has announced the funding and initiation of an open-label exploratory trial evaluating its lead drug, voclosporin in kidney transplant recipients with COVID-19.This 56-day open-label investigator initiated trial is designed to evaluate the antiviral effects...
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple indications, today announced the funding and initiation of an open-label explor...
Aurinia Pharmaceuticals (AUPH) has announced that integrated efficacy and pharmacokinetic data from AURA-LV and AURORA pivotal trials of voclosporin in lupus nephritis ((LN)) were presented at the American Society of Nephrology Kidney Week.Integrated data from 534 patients from both the trial...
- Integrated analysis confirms statistically superior efficacy and safety of voclosporin in combination with MMF and steroids over standard-of-care – - Voclosporin pharmacokinetic data supports consistent dose-response, potentially eliminating the need for therapeutic d...
News, Short Squeeze, Breakout and More Instantly...
Aurinia Pharmaceuticals Inc Company Name:
AUPH Stock Symbol:
NASDAQ Market:
Aurinia Pharmaceuticals Inc Website:
Viridien ADR (CGGYD) is expected to report for Q2 2024 Civitas Resources Inc. (CIVI) is expected to report $2.9 for Q2 2024 Aptiv PLC (APTV) is expected to report $1.37 for Q2 2024 Ardelyx Inc. (ARDX) is expected to report $-0.1 for Q2 2024 Beazer Homes USA Inc. (BZH) is expected ...
Company achieved $57.2 million in total net revenue and $55.0 million in net product revenue for the second quarter of 2024, representing year-over-year growth of approximately 38% and 34% respectively Company generated approximately $15.8 million in free cash flow in the second quarter a...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the second quarter of 2024 on Thursday, August 1, 2024, before markets open. Aurinia’s management team will host a conference call/webcast at 8:30...